AndreaBozzo/ceres-open-data-index huggingface dataset:
Regional Partnership Grants National Cross-Site Evaluation: Round Three Sites (RPG-3)

To address the far-reaching consequences of adult substance use disorders on families and children, Congress in 2006 authorized, and in 2011 reauthorized, competitive grants to support partnerships among child welfare, substance use disorder treatment, and related organizations. The Children’s Bureau (CB) within the Administration for Children and Families, Administration on Children, Youth and Families at the U.S. Department of Health and Human Services established the Regional Partnership Grant (RPG) program, and in 2012 awarded grants to 17 second-cohort (RPG-2) partnerships to implement evidence-based programs (EBPs) to meet the needs of this target population. These data are available as NDACAN dataset 218.
As noted in the NDACAN dataset 218 description, CB funded Mathematica Policy Research, along with its subcontractor Walter R. MacDonald & Associates (WRMA), to conduct a five-year cross-site evaluation of the grantees’ RPG projects. Mathematica and WRMA designed a cross-site evaluation to address the following 7 research questions:

Investigators: Strong, D., Avellar, S., Cole, R., & D'Angelo, A.
NNDSS - Table 1I. Cryptosporidiosis to Cyclosporiasis

NNDSS - Table 1I.  Cryptosporidiosis to Cyclosporiasis - 2020. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Note: 
This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. 

Footnotes:
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
* Case counts for reporting years 2019 and 2020 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf.
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
Amyloid associated with elastin-staining laminar aggregates in the lungs of patients diagnosed with acute respiratory distress syndrome

Background
          The heterogeneity of conditions underlying respiratory distress, whether classified clinically as acute lung injury (ALI) or the more severe acute respiratory distress syndrome (ARDS), has hampered efforts to identify and more successfully treat these patients. Examination of postmortem lungs among cases clinically diagnosed as ARDS identified a cohort that showed a consistent morphology at the light and electron microscope levels, and featured pathognomonic structures which we termed elastin-staining laminar structures (ELS).
        
        
          Methods
          Postmortem tissues were stained using the Verhoeff-Van Gieson procedure for elastic fibers, and with Congo red for examination under a polarizing microscope. Similar samples were examined by transmission EM.
        
        
          Results
          The pathognomonic ELS presented as ordered molecular aggregates when stained using the Verhoeff-van Gieson technique for elastic fibers. In several postmortem lungs, the ELS also displayed apple-green birefringence after staining with Congo red, suggesting the presence of amyloid. Remarkably, most of the postmortem lungs with ELS exhibited no significant acute inflammatory cellular response such as neutrophilic reaction, and little evidence of widespread edema except for focal intra-alveolar hemorrhage.
        
        
          Conclusions
          Postmortem lungs that exhibit the ELS constitute a morphologically-identifiable subgroup of ARDS cases. The ordered nature of the ELS, as indicated by both elastin and amyloid stains, together with little morphological evidence of inflammation or edema, suggests that this cohort of ARDS may represent another form of conformational disease. If this hypothesis is confirmed, it will require a new approach in the diagnosis and treatment of patients who exhibit this form of acute lung injury.
National Survey on Drug Use and Health: 8-Year R-DAS (NSDUH-2002-2009)

<p>This file includes data from the 2002 through 2009 National Survey on Drug Use and Health (NSDUH) survey. The only variables included in the 8-year 2002-2009 data file are ones that were collected in a comparable manner across all 8 years.<br />
The National Survey on Drug Use and Health (NSDUH) series (formerly titled National Household Survey on Drug Abuse) primarily measures the prevalence and correlates of drug use in the United States. The surveys are designed to provide quarterly, as well as annual, estimates. Information is provided on the use of illicit drugs, alcohol, and tobacco among members of United States households aged 12 and older. Questions included age at first use as well as lifetime, annual, and past-month usage for the following drug classes: marijuana, cocaine (and crack), hallucinogens, heroin, inhalants, alcohol, tobacco, and nonmedical use of prescription drugs, including pain relievers, tranquilizers, stimulants, and sedatives. The survey covered substance abuse treatment history and perceived need for treatment. The survey included questions concerning treatment for both substance abuse and mental health-related disorders. Respondents were also asked about personal and family income sources and amounts, health care access and coverage, illegal activities and arrest record, problems resulting from the use of drugs, and needle-sharing. Certain questions are asked only of respondents aged 12 to 17. These "youth experiences" items covered a variety of topics, such as neighborhood environment, illegal activities, drug use by friends, social support, extracurricular activities, exposure to substance abuse prevention and education programs, and perceived adult attitudes toward drug use and activities such as school work. Also included are questions on mental health and access to care, perceived risk of using drugs, perceived availability of drugs, driving and personal behavior, and cigar smoking. Demographic information includes sex, race, age, ethnicity, marital status, educational level, job status, veteran status, and current household composition.<br />
In the income section, which was interviewer-administered, a split-sample study had been embedded within the 2006 and 2007 surveys to compare a shorter version of the income questions with a longer set of questions that had been used in previous surveys. This shorter version was adopted for the 2008 NSDUH and will be used for future NSDUHs.This study has 1 Data Set.</p>
National Household Survey on Drug Abuse (NHSDA-1990)

<p>This series measures the prevalence and correlates of drug use in the United States. The surveys are designed to provide quarterly, as well as annual, estimates. Information is provided on the use of illicit drugs, alcohol, anabolic steroids, and tobacco among members of United States households aged 12 and older. Questions include age at first use, as well as lifetime, annual, and past-month usage for the following drug classes: marijuana, inhalants, cocaine, hallucinogens, heroin, alcohol, tobacco, and nonmedical use of psychotherapeutics. Respondents were also asked about problems resulting from their use of drugs, alcohol, and tobacco, their perceptions of the risks involved, insurance coverage, and personal and family income sources and amounts. Demographic data include sex, race, ethnicity, educational level, job status, income level, household composition, and population density. This study has 1 Data Set.</p>
Publications Using SAMHSA DataBehavioral Health Barometer: HHS Region IV, 2014

This is a behavioral health report for HHS Region IV of the United States and utilizes data from the National Survey on Drug Use and Health (NSDUH) and the National Survey of Substance Abuse Treatment (N-SSATS), collected annually. The topics addressed in the reports include youth mental health and treatment, adult mental health, substance use and substance use treatment.
Compound 528330: Furfuryl propyl sulfide

Chemical compound data from PubChem database. IUPAC Name: 1-(propylsulfanylmethyl)cyclopenta-1,3-diene. Molecular Formula: C9H14S. Molecular Weight: 154.27. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526473: Propyl perfluoroheptanoate

Chemical compound data from PubChem database. IUPAC Name: propyl 2,2,3,3,4,4,5,5,6,6,7,7,7-tridecafluoroheptanoate. Molecular Formula: C10H7F13O2. Molecular Weight: 406.14. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 527078: Tetratriacontane, 10,14,18-trimethyl

Chemical compound data from PubChem database. IUPAC Name: 10,14,18-trimethyltetratriacontane. Molecular Formula: C37H76. Molecular Weight: 521.0. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Child and Family Services Reviews Update Volume 13, Issue 2, March 2019

This issue of Child and Family Services Reviews Update contains the following sections: Request for Public Comment on Statewide Data Indicators Extended, Revised State Data Profiles Disseminated, Recent Personnel Changes in the CFSR Unit, Program Improvement Plan Approvals Progressing for Round 3 CFSRs, and Focus on Youth CFSR Findings: 2015–2017.

Metadata-only record linking to the original dataset. Open original dataset below.
Mapping of the Mouse Actin Capping Protein Beta Subunit Gene

Background
          Capping protein (CP), a heterodimer of α and β subunits, is found in all eukaryotes. CP binds to the barbed ends of actin filaments in vitro and controls actin assembly and cell motility in vivo. Vertebrates have three isoforms of CPβ produced by alternatively splicing from one gene; lower organisms have one gene and one isoform.
        
        
          Results
          We isolated genomic clones corresponding to the β subunit of mouse CP and identified its chromosomal location by interspecies backcross mapping.
        
        
          Conclusions
          The CPβ gene (Cappb1) mapped to Chromosome 4 between Cdc42 and D4Mit312. Three mouse mutations, snubnose, curly tail, and cribriform degeneration, map in the vicinity of the β gene.
Compound 526783: 7-Hydroxy-stearic acid, methyl ester, tBDMS ether

Chemical compound data from PubChem database. IUPAC Name: methyl 7-[tert-butyl(dimethyl)silyl]oxyoctadecanoate. Molecular Formula: C25H52O3Si. Molecular Weight: 428.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Skilled Nursing Facility Enrollments

The Skilled Nursing Facility (SNF) Enrollments dataset provides enrollment information of all SNF 's currently enrolled in Medicare. This data includes information on the SNF's legal business name, doing business as name, organization type and address.

 

On November 17, 2023, CMS published in the Federal Register a final rule titled, “Medicare and Medicaid Programs; Disclosures of Ownership and Additional Disclosable Parties Information for Skilled Nursing Facilities and Nursing Facilities; Medicare Providers’ and Suppliers’ Disclosure of Private Equity Companies and Real Estate Investment Trusts” (88 FR 80141). This final rule implements parts of section 1124(c) of the Act which requires SNFs to disclose detailed information about their ownership and management as well as additional data regarding: (1) other parties with which the SNF is associated; and (2) the ownership structures of these other parties.  Refer to Medicare Enrollment for Providers & Suppliers for more information on the Skilled Nursing Facility disclosure requirements.

Section 6101(b) of the Affordable Care Act states that no later than 1 year after final regulations promulgated under section 1124(c) of the Act are published in the Federal Register, the Secretary shall make the information reported available to the public.

 On November 21, 2024 CMS updated this dataset to include this reported information.
New York AFCARS Assessment Review

This webpage includes the documentation from New York's Adoption and Foster Care Analysis and Reporting System (AFCARS) assessment review for fiscal year 2012:

AFCAR Assessment Review Findings - Letter (PDF - 78 KB)

AFCARS Assessment Review Report - New York (PDF - 181 KB)

AFCARS Assessment Review Findings - General Requirement (PDF - 310 KB)

AFCARS Assessment Review Findings - Foster Care and Adoption Data Elements (PDF - 562 KB)

AFCARS Case File Summary Report - New York (PDF - 78 KB)

AFCARS Assessment Review Case File Findings - Foster Care and Adoption Data Elements (PDF - 228 KB)

AFCARS Assessment Review Improvement Plan - General Requirements (PDF - 293 KB)

AFCARS Assessment Review Improvement Plan - Foster Care and Adoption Data Elements (PDF - 576 KB)

Metadata-only record linking to the original dataset. Open original dataset below.
The inhibitory effects of camptothecin, a topoisomerase I inhibitor, on collagen synthesis in fibroblasts from patients with systemic sclerosis

The main manifestation of systemic sclerosis (SSc) is the overproduction of extracellular matrix, predominantly type I collagen. This study was undertaken to evaluate the effects of noncytotoxic doses of the topoisomerase I inhibitor camptothecin (CPT) on collagen production in the activated dermal fibroblasts from patients with SSc and healthy donors. The fibroblasts were cultured in the presence or absence of CPT. Production of collagenous proteins by fibroblasts was determined in cell and matrix layers by ELISA and in conditioned media by [3H]proline incorporation, gel electrophoresis, and autoradiography. Expression of α2(I) collagen (COL1A2) mRNA was measured by northern blot, and the activity of COL1A2 promoter was determined by a chloramphenicol acetyltransferase assay. CPT (10-7 M) decreased the deposition of type I collagen by 68%, of type III by 38%, and of type VI by 21% in SSc fibroblasts and to a lesser degree in healthy controls. Similarly, CPT (10-8 M to 10-6 M) significantly inhibited secretion of newly synthesized collagenous proteins into conditioned media by 50%. CPT (10-8 M to 10-6 M) caused a significant dose-dependent inhibition of COL1A2 mRNA levels and COL1A2 promoter activity, both by as much as 60%. The inhibitory effect of CPT on collagen production by fibroblasts from patients with SSc suggests that topoisomerase I inhibitors may be effective in limiting fibrosis in such patients.
Advance Planning Document (APD) Checklist for Automated Functions (optional)

This Information Memorandum (IM) provides title IV-E agencies that choose to develop a CCWIS and expect expenditures to meet or exceed thresholds defined in APD regulations with information on the use of an optional checklist to document automated functions as described in CCWIS regulations at 45 CFR 1355.56.

Metadata-only record linking to the original dataset. Open original dataset below.
Montana: 2011-2012 NSDUH

This report presents Montana\'s estimates for 25 measures of substance use and mental health based on the combined 2011 and 2012 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided by State and for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
New York State Statewide COVID-19 Fatalities by County

This dataset includes the cumulative number of healthcare facility-reported fatalities for patients with lab-confirmed COVID-19 disease by reporting date, patient county of residence, and patient fatalities that occurred based on the facility county. This dataset does not include fatalities related to COVID-19 disease that did not occur at a hospital, nursing home, or adult care facility. The primary goal of publishing this dataset is to provide users with information about healthcare facility fatalities among patients with lab-confirmed COVID-19 disease. 

The information in this dataset is also updated daily on the NYS COVID-19 Tracker at https://www.ny.gov/covid-19tracker.
The data source for this dataset is the daily COVID-19 survey through the New York State Department of Health (NYSDOH) Health Electronic Response Data System (HERDS). Hospitals, nursing homes, and adult care facilities are required to complete this survey daily. The information from the survey is used for statewide surveillance, planning, resource allocation, and emergency response activities. Hospitals began reporting for the HERDS COVID-19 survey in March 2020, while Nursing Homes and Adult Care Facilities began reporting in April 2020. It is important to note that fatalities related to COVID-19 disease that occurred prior to the first publication dates are also included.

The county fatality numbers in this dataset are calculated by summing the number of fatalities by patient county of residence and reporting date, and patient fatalities that occurred based on the facility county, respectively. The statewide fatality numbers are calculated by summing the number of fatalities across all patient counties of residence, and across all facilities by county, by reporting date, respectively. The fatality numbers represent the cumulative number of fatalities that have been reported as of each reporting date.
2012 Uniform Reporting System (URS) Tables for Louisiana

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2012. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Patent AT-E401839-T1: [Translated] COATED STENT WITH IMPROVED GRIP PROPERTIES

A medical device delivery apparatus is provided which comprises a catheter having an expandable and contractible member and an expandable medical device disposed about the expandable and contractible member. At least portions of at least one of the medical device and the expandable and contractible member have a pressure sensitive adhesive applied thereto to adhere the medical device to the expandable and contractible member. The pressure sensitive adhesive is selected so as to release the medical device from the expandable and contractible member upon contraction of the member from an expanded state. Suitable medical devices include stents.
Evaluation of Child Care Subsidy Strategies: Washington Site Public Use Files, 2005

The Evaluation of Child Care Subsidy Strategies is a multi-site, multi-year effort to determine whether and how different child care subsidy policies and procedures and quality improvement efforts help low-income parents obtain and hold onto jobs and improve outcomes for children. Funding from the Child Care and Development Fund (CCDF) administered by the Child Care Bureau are divided into two purposes. The vast majority are aimed at assisting children of low-income working parents whose eligibility is determined by states within broad federal guidelines, while a much smaller portion (4 percent) work with state matching funds to improve the quality of child care for all children. For this study series, four experiments were conducted, two test alternative subsidy policies for low-income families and two test approaches to the use of set-aside funds for improving child care quality for all children. The four study sites and focus of evaluation include: (1) the effectiveness of three language and literacy curricula on teaching practices and children's language and literacy outcomes (Miami Dade County, Florida); (2) the impact of alternative eligibility and re-determination child care subsidy policies on parental employment outcomes (Illinois); (3) the impact of alternative child care co-payment structures on use of child care subsidies and employment outcomes (Washington) and (4) the effectiveness of training on Learning Games curriculum in changing care-giving practices in family child care homes and children's developmental outcomes (Massachusetts).

<b>Units of Response: </b>Washington state families receiving child care subsidies.

<b>Type of Data: </b>Administrative

<b>Tribal Data: </b>No

<b>Periodicity: </b>One-time

<b>Demographic Indicators: </b>Household Income;Household Size;Race

<b>SORN: </b>https://www.federalregister.gov/documents/2022/09/19/2022-20139/privacy-act-of-1974-system-of-records

<b>Data Use Agreement: </b>Yes

<b>Data Use Agreement Location: </b>https://www.icpsr.umich.edu/web/ICPSR/studies/29002/datadocumentation

<b>Granularity: </b>Family;Household

<b>Spatial: </b>States

<b>Geocoding: </b>Unavailable
Compound 528254: 3,5-Dimethyl-2-propylthiophene

Chemical compound data from PubChem database. IUPAC Name: 3,5-dimethyl-2-propylthiophene. Molecular Formula: C9H14S. Molecular Weight: 154.27. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525595: N,N-Dimethyl-N'-(4-ethoxyphenyl)-p-chlorobenzamidine

Chemical compound data from PubChem database. IUPAC Name: 4-chloro-N'-(4-ethoxyphenyl)-N,N-dimethylbenzenecarboximidamide. Molecular Formula: C17H19ClN2O. Molecular Weight: 302.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.